Effect of dual delivery of antibiotics (vancomycin and cefazolin) and BMP-7 from chitosan microparticles on Staphylococcus epidermidis and pre-osteoblasts in vitro.
The main aims of this manuscript are to: i) determine the effect of commonly used antibiotics to treat osteoarticular infections on osteoblast viability, ii) study the dual release of the growth factor (BMP-7) and antibiotics (vancomycin and cefazolin) from chitosan microparticles iii) demonstrate the bioactivity of the antibiotics released in vitro on Staphylococcus epidermidis. The novelty of this work is dual delivery of growth factor and antibiotic from the chitosan microparticles in a controlled manner without affecting their bioactivity. Cefazolin and vancomycin have different therapeutic concentrations for their action in vivo and therefore, two different concentrations of the drugs were used. Osteoblast cytotoxicity test concluded that cefazolin concentrations of 50 and 100μg/ml were found to have positive influence on osteoblast proliferation. A significant increase in osteoblast proliferation was observed in the presence of cefazolin and BMP-7 in comparison with BMP-7 alone group; indicating cefazolin might play a role in osteoblast proliferation. On the other hand, vancomycin concentration of 1000μg/ml was found to significantly reduce (p<0.01) osteoblast proliferation in comparison with controls. The microbial study indicated that cefazolin at a minimum concentration of 21.5μg/ml could inhibit ~85% growth of S. epidermidis, whereas vancomycin at a concentration of 30μg/ml was found to inhibit ~80% bacterial growth.
Biomedical Engineering Program, The University of Toledo, Toledo, OH 43614-5807, USA.
Venkata P
VP
Mantripragada
Biomedical Engineering Program, The University of Toledo, Toledo, OH 43614-5807, USA; Department of Orthopaedic Surgery, The University of Toledo, Toledo, OH 43614-5807, USA. Electronic address: a.jayasuriya@utoledo.edu.
Ambalangodage C
AC
Jayasuriya
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D055419:Bone Morphogenetic Protein 7 / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D002437:Cefazolin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism*; D013212:Staphylococcus epidermidis / Q000254:growth & development*; D014640:Vancomycin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
D000900:Anti-Bacterial Agents; C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D003692:Delayed-Action Preparations; D014640:Vancomycin; D002437:Cefazolin
BMP-7; Cefazolin; Chitosan microparticles; Osteoblast; Staphylococcus epidermidis; Vancomycin